About Cagrilintide
Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination
Cagrilintide is a long-acting synthetic amylin analogue under clinical development for obesity, designed to mimic the satiety-promoting and gastric-emptying-reducing actions of the endogenous beta-cell hormone amylin. By activating amylin receptors in the hindbrain, cagrilintide reduces caloric intake and body weight, and the drug is also being co-developed with the GLP-1 receptor agonist semaglutide (CagriSema) to target multiple appetite-regulating pathways simultaneously. Phase 2 randomized controlled trials published in The Lancet have demonstrated meaningful weight reduction in people with overweight and obesity, establishing proof of concept for both monotherapy and combination approaches. Cagrilintide is an investigational compound that has not yet received FDA approval; it remains in late-stage clinical development as of 2025.
Cagrilintide Benefits & Research Areas
Research Signals
Commonly researched in the context of
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Moderate risk profile in research contexts. Review contraindications and administration guidelines before use.
Regulatory Status
- Availability Status
- Research Only
- FDA Status
- Investigational
- Source
- View FDA source →
Amylin analog by Novo Nordisk. Phase 3 as CagriSema (+ semaglutide, NCT05669755) for obesity. Not yet approved. NDA submission anticipated 2026-2027 if trials succeed.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
8 sources cited · 4 strong · 4 moderate
4 RCTs · 1 Meta-analysis · 3 Reviews
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.
Endocrinol Diabetes Metab · 2026
# Summary Research found that novel amylin-based therapies demonstrated greater reductions in body weight compared to established anti-obesity medications, with high-dose amycretin producing the largest weight loss effect in adults with overweight or obesity. This study observed that while these therapies showed substantial weight-loss benefits, they were associated with increased gastrointestinal adverse events, particularly nausea, vomiting, and constipation.
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
Lancet Diabetes Endocrinol · 2026
# Summary Research found that the combination of cagrilintide and semaglutide produced greater bodyweight reductions compared to semaglutide alone in adults with overweight or obesity in Japan and Taiwan. This phase 3a trial demonstrated the efficacy of the fixed-dose combination treatment in an East Asian population, with or without type 2 diabetes.
Combination of cagrilintide and semaglutide 2·4 mg for weight management in adults with overweight and obesity (CagriSema): a randomised, 1:1:1, double-blind, active-controlled, phase 2 trial
Lancet · 2023
Research in a phase 2 trial found that the combination of cagrilintide 2.4 mg and semaglutide 2.4 mg (CagriSema) reduced mean body weight by 15.6% over 32 weeks, significantly exceeding reductions achieved with semaglutide alone (-5.1%) or cagrilintide alone (-8.1%), suggesting synergistic weight-loss effects.
Show 5 more sources ↓
Cagrilintide 2·4 mg once-weekly subcutaneous injection in adults with overweight or obesity (SCALE-CAGRI): a randomised, double-blind, placebo-controlled trial
Lancet · 2021
In a 26-week phase 2 trial, once-weekly cagrilintide 2.4 mg reduced mean body weight by 10.8% compared with 3.0% for placebo in adults with overweight or obesity, with all doses showing dose-dependent weight reduction and a tolerability profile consistent with amylin receptor agonism.
Beyond weight loss: multisystem benefits of obesity medications.
Lancet Diabetes Endocrinol · 2026
I appreciate you sharing this document, but I need to point out that what you've provided is only the title and conflict of interest statement—not the actual abstract or research findings about Cagrilintide. To provide an accurate, educational summary of the primary finding regarding Cagrilintide, I would need access to the full abstract and methods/results sections of the paper. Could you share the complete abstract and findings section? That way I can give you a precise, factual summary using the educational framing you requested.
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
Metabol Open · 2026
# Summary Research found that cagrilintide, a long-acting amylin pathway analog, achieves weight reductions up to 24% by activating distinct neuroendocrine circuits independent of GLP-1 receptor mechanisms. This study demonstrated that amylin-based approaches represent an emerging therapeutic strategy in the next generation of obesity pharmacotherapy beyond traditional GLP-1 receptor agonists.
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.
J Diabetes Metab Disord · 2026
# Summary Research found that cagrilintide, both alone and in combination with semaglutide (CagriSema), produced clinically meaningful reductions in body weight compared to placebo in adults with overweight or obesity, with CagriSema additionally demonstrating improvements in waist circumference and blood sugar levels. This study demonstrated that both treatments were associated with acceptable tolerability, supporting their potential role as pharmacologic options for obesity management.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Lancet · 2021
Cagrilintide co-administered with semaglutide 2.4 mg once-weekly was well tolerated. Mean body weight reductions of 15.4–17.1% at 20 weeks with the combination versus 8.0–9.8% with semaglutide-matched placebo cohorts. Most adverse events were mild-to-moderate gastrointestinal events; no pharmacokinetic interaction between compounds.
Cagrilintide Side Effects & Safety Considerations
Moderate risk profile. Review all reported considerations carefully before use.
Reported contraindications & considerations
Common monitoring markers in research protocols
Given mechanistic overlap with GLP-1 agonists when used as CagriSema, monitor thyroid C-cell markers (calcitonin), lipase for pancreatitis risk, and a baseline metabolic panel. Amylin-specific monitoring guidance is evolving as Phase 3 data matures; follow prescribing protocol of the co-administered agent.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy Cagrilintide — Providers & Availability
13 providersClinics
4 providersCompounding Pharmacies (503A)
1 providerStay updated on verified Cagrilintide providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Cagrilintide
Cagrilintide is a long-acting synthetic amylin analogue under clinical development for obesity, designed to mimic the satiety-promoting and gastric-emptying-reducing actions of the endogenous beta-cell hormone amylin. By activating amylin receptors in the hindbrain, cagrilintide reduces caloric intake and body weight, and the drug is also being co-developed with the GLP-1 receptor agonist semaglutide (CagriSema) to target multiple appetite-regulating pathways simultaneously.
Fat Loss.
Research on Cagrilintide primarily documents effects related to Fat Loss. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Cagrilintide include active cancer history, pregnant or nursing. This is educational information only — consult a qualified healthcare professional before use.
13 providers in the directory currently offer Cagrilintide.
# Summary Research found that novel amylin-based therapies demonstrated greater reductions in body weight compared to established anti-obesity medications, with high-dose amycretin producing the largest weight loss effect in adults with overweight or obesity. This study observed that while these therapies showed substantial weight-loss benefits, they were associated with increased gastrointestinal adverse events, particularly nausea, vomiting, and constipation.